Selank
Selank (TP-7)
A synthetic heptapeptide developed in Russia with anxiolytic and nootropic properties studied in clinical trials. Approved in Russia for generalized anxiety.
Selank is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
Selank is a synthetic analogue of the naturally occurring tetrapeptide tuftsin (Thr-Lys-Pro-Arg). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has undergone clinical trials in Russia with regulatory approval there for generalized anxiety disorder.
It has a unique pharmacological profile — anxiolytic without the sedation or dependence associated with benzodiazepines.
What research shows
- Anxiolytic effects comparable to benzodiazepines without sedation or dependence in Russian trials
- Improved cognitive function, memory, and attention in some studies
- Upregulation of BDNF
- Immune modulatory effects — affects IL-6 and interferon expression
What remains unknown
- Reproducibility in Western clinical trial frameworks
- Long-term safety profile
- Exact mechanism underlying nootropic effects
Administration basics
Common use cases
Anxiety, cognitive enhancement, stress management.
Half-life
~1–2 minutes in blood (but CNS effects last much longer).
Administration
Intranasal drops or subcutaneous injection. Intranasal is most common.
Source this compound
Looking for Selank?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Russian clinical trials have used 250–500mcg intranasally per day
- Community protocols commonly report similar doses of 250–500mcg/day
Administration routes studied
Typical protocol duration
Russian research protocols commonly ran 2–4 weeks. Community use includes both short cycles and longer maintenance protocols.
Common stacking protocols
- Selank + Semax — the most commonly reported nootropic/anxiolytic combination
- Selank + BPC-157 — combined in some anxiety-reduction protocols
Contraindications & combinations to avoid
- Benzodiazepines and other anxiolytics — additive effects on anxiety pathways are possible
- Psychiatric medications — caution when combining with medications acting on GABA or serotonin pathways
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with Selank and what to avoid.
Track your Selank protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the Selank page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.